| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 10, 2011Campaign Empowers People With a Slow Heartbeat to Learn About Treatment Options and How to Have an Informed Discussion With Their Doctor
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off "Join the Pace Makers," a national campaign designed to empower people with a...
-
Nov 9, 2011
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal...
-
Nov 9, 2011Study Will Evaluate Accuracy of Latest Innovation to Help People with Diabetes Improve Glucose Control
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in...
-
Nov 8, 2011Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device's Consistently Positive Performance Across Multiple Clinical Studies
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT)...
-
Nov 8, 2011Final Five-Year Follow-up of Randomized ENDEAVOR IV Trial Shows Durable Safety and Efficacy of Endeavor DES, with Comparatively Lower Rates of Cardiac Death/Myocardial Infarction and Very Late Stent Thrombosis
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- New research findings released at TCT 2011 show that the Endeavor(R) zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed...